Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

AstraZeneca signs CSPC China deal for experimental kidney disease drugs | PharmaVoice

ET Pharma

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

Jul 3, 2026, 1:45 AM

Read Full Article →

Translate article text

Choose a language and wait for the translated text.

CSPC is eligible to receive $30 million as an upfront payment and ‌up to about $1.74 billion in additional payments tied to development and sales-related milestones